Scalp Psoriasis

  • Daniel Asz-Sigall
  • Antonella Tosti


About 80% of patients with psoriasis have some degree of scalp involvement, and most of them report a negative impact on their quality of life. Scalp psoriasis treatment is challenging because the presence of hair makes it difficult to apply certain products. Shampoos, lotions, gels, and foams are preferable to thicker creams and ointments. High-potency topical corticosteroids are the first-line treatment, used alone or in combination with vitamin D analogs. Other topical therapies include coal tar, salicylic acid, tazarotene, and anthralin. Phototherapy and systemic agents are other alternatives for patients who do not achieve sufficient improvement with topical agents. Despite the wide range of available therapies, long-term management has been unsatisfactory, often because of the safety of chronic drug use.


Psoriasis Scalp psoriasis Topical corticosteroids Vitamin D analogs Phototherapy Systemic treatment Biologic agents 


  1. 1.
    Van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2:159–65.PubMedGoogle Scholar
  2. 2.
    Van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197:326–34.PubMedGoogle Scholar
  3. 3.
    Guenther L. Current management of scalp psoriasis. Skin Therapy Lett. 2015;20(3):5–7.PubMedGoogle Scholar
  4. 4.
    Wang TS, Tsai TF. Managing scalp psoriasis: an evidence-based review. Am J Clin Dermatol. 2017;18(1):17–43.PubMedGoogle Scholar
  5. 5.
    Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–4.PubMedGoogle Scholar
  6. 6.
    Feldman SR. Treatment of psoriasis in adults. In: Post TW, editor. UpToDate. Waltham: UptoDate Inc. Accessed on January 2019.
  7. 7.
    Tosti A. Dermoscopy of the hair and nails. 2nd ed. Boca Raton: CRC Press; 2016. p. 115.Google Scholar
  8. 8.
    Rossi A, Mandel VD, Garelli V, Mari E, Fortuna MC, Carlesimo M, et al. Videodermoscopy scalp psoriasis severity index (VSCAPSI): a useful tool for evaluation of scalp psoriasis. Eur J Dermatol. 2011;21(4):546–51.PubMedGoogle Scholar
  9. 9.
    Williams RE. Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists. BMJ. 1991;303:829–35.Google Scholar
  10. 10.
    Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges. 2007;5(Suppl. 3):1–119.PubMedGoogle Scholar
  11. 11.
    Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician. 2000;61:725–33, 736.PubMedGoogle Scholar
  12. 12.
    Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21:1151–60.PubMedGoogle Scholar
  13. 13.
    Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002;146:351–64.PubMedGoogle Scholar
  14. 14.
    Osier E, Gomez B, Eichenfield LF. Adolescent scalp psoriasis: update on topical combination therapy. J Clin Aesthet Dermatol. 2015;8(7):43–7.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3396 patients. Dermatology. 2001;203:153–6.PubMedGoogle Scholar
  16. 16.
    Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320:963.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis. An open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol. 2003;148:134–8.PubMedGoogle Scholar
  18. 18.
    Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol. 2004;3:367–73.PubMedGoogle Scholar
  19. 19.
    Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther. 1995;17:390–401.PubMedGoogle Scholar
  20. 20.
    Mazzotta A, Esposito M, Carboni I, Schipani C, Chimenti S. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat. 2007;18:84–7.PubMedGoogle Scholar
  21. 21.
    Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol. 1994;130:483–7.PubMedGoogle Scholar
  22. 22.
    Ruzicka T, Trompke C. Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion. Hautarzt. 2004;55:165–70; (in German).PubMedGoogle Scholar
  23. 23.
    Klaber MR, Hutchinson PE, Pedvis-Leftick A, Kragballe K, Reunala TL, Van de Kerkhof PC, et al. Comparative effects of calcipotriol solution (50 micrograms/mL) and betamethasone 17-valerate solution (1 mg/mL) in the treatment of scalp psoriasis. Br J Dermatol. 1994;131:678–83.PubMedGoogle Scholar
  24. 24.
    Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdulla SA. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res. 2000;20:65–8.PubMedGoogle Scholar
  25. 25.
    Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol. 2004;13:106.PubMedGoogle Scholar
  26. 26.
    Faergemann J, Diehl U, Bergfelt L, Brodd A, Edmar B, Hersle K, et al. Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol. Acta Derm Venereol. 2003;83(6):438–41.PubMedGoogle Scholar
  27. 27.
    Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis. 1983;32:290–6.PubMedGoogle Scholar
  28. 28.
    Sekhon S, Jeon C, Nakamura M, Afifi L, Yan D, Wu JJ, et al. Review of the mechanism of action of coal tar in psoriasis. J Dermatolog Treat. 2018;29:230.PubMedGoogle Scholar
  29. 29.
    Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol. 2009;61:294.PubMedGoogle Scholar
  30. 30.
    Going SM, Guyer BM, Jarvie DR, Hunter JA. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol. 1986;11:260–2.PubMedGoogle Scholar
  31. 31.
    Kircik L. Salicylic acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. J Drugs Dermatol. 2011;10(3):270–3.PubMedGoogle Scholar
  32. 32.
    Shokeen D, O’Neill JL, Taheri A, Feldman SR. Are topical keratolytic agents needed in the treatment of scalp psoriasis? Dermatol Online J. 2014;20(3).
  33. 33.
    Jekler J, Swanbeck G. One-minute dithranol therapy in psoriasis: a placebo-controlled paired comparative study. Acta Derm Venereol. 1992;72:449.PubMedGoogle Scholar
  34. 34.
    Oostveen AM, Beulens CA, van de Kerkhof PC, de Jong EM, Seyger MM. The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. Br J Dermatol. 2014;170:454.PubMedGoogle Scholar
  35. 35.
    Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol. 2004;17(2):91–7.PubMedGoogle Scholar
  36. 36.
    Veraldi S, Caputo R, Pacifico A, Peris K, Soda R, Chimenti S. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology. 2006;212:235.PubMedGoogle Scholar
  37. 37.
    Gollnick H, Menter A. Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol. 1999;140(Suppl 54):18.PubMedGoogle Scholar
  38. 38.
    Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev. 2013;(10):CD009481.Google Scholar
  39. 39.
    Anderson KL, Feldman SR. A guide to prescribing home phototherapy for patients with psoriasis: the appropriate patient, the type of unit, the treatment regimen, and the potential obstacles. J Am Acad Dermatol. 2015;72:868.PubMedGoogle Scholar
  40. 40.
    Koek MB, Buskens E, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Sigurdsson V. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ. 2009;338:b1542.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study. Int J Dermatol. 2004;43(6):462–7.PubMedGoogle Scholar
  42. 42.
    Walters IB, Burack LH, Coven TR, Gilleaudeau P, Krueger JG. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol. 1999;40:893.PubMedGoogle Scholar
  43. 43.
    Rose RF, Batchelor RJ, Turner D, Goulden V. Narrowband ultraviolet B phototherapy does not influence serum and red cell folate levels in patients with psoriasis. J Am Acad Dermatol. 2009;61:259.PubMedGoogle Scholar
  44. 44.
    Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med. 2007;357:682.PubMedGoogle Scholar
  45. 45.
    Berneburg M, Herzinger T, Rampf J, Hoetzenecker W, Guenova E, Meisner C, et al. Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. Br J Dermatol. 2013;169:704.PubMedGoogle Scholar
  46. 46.
    Wong JW, Kamangar F, Nguyen TV, Koo JY. Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm. Skin Therapy Lett. 2012;17(5):6–9.PubMedGoogle Scholar
  47. 47.
    Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. 2002;46:900.Google Scholar
  48. 48.
    Gerber W, Arheilger B, Ha TA, Hermann J, Ockenfels HM. Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach. Br J Dermatol. 2003;149:1250.PubMedGoogle Scholar
  49. 49.
    Gattu S, Rashid RM, Wu JJ. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):36–41.PubMedGoogle Scholar
  50. 50.
    Morison WL, Atkinson DF, Werthman L. Effective treatment of scalp psoriasis using the excimer (308 nm) laser. Photodermatol Photoimmunol Photomed. 2006;22(4):181–3.PubMedGoogle Scholar
  51. 51.
    Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol. 2006;33:1442.PubMedGoogle Scholar
  52. 52.
    Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961.PubMedGoogle Scholar
  53. 53.
    Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478.PubMedGoogle Scholar
  54. 54.
    Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824.PubMedGoogle Scholar
  55. 55.
    Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133:711.PubMedGoogle Scholar
  56. 56.
    Tanew A, Guggenbichler A, Hönigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25:682.PubMedGoogle Scholar
  57. 57.
    Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001;45:544.PubMedGoogle Scholar
  58. 58.
    Faerber L, Braeutigam M, Weidinger G, Mrowietz U, Christophers E, Schulze HJ, et al. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am J Clin Dermatol. 2001;2:41.PubMedGoogle Scholar
  59. 59.
    Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol. 1999;141:283.PubMedGoogle Scholar
  60. 60.
    Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842.PubMedGoogle Scholar
  61. 61.
    Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24:1529.PubMedGoogle Scholar
  62. 62.
    Fotiadou C, Lazaridou E, Sotiriou E, Kyrgidis A, Apalla Z, Ioannides D. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre. J Eur Acad Dermatol Venereol. 2016;30(12):2091–6.PubMedGoogle Scholar
  63. 63.
    Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol. 2006;33:1447.PubMedGoogle Scholar
  64. 64.
    Shalom G, Zisman D, Bitterman H, Harman-Boehm I, Greenberg-Dotan S, Dreiher J, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015;151:533.PubMedGoogle Scholar
  65. 65.
    Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47.PubMedGoogle Scholar
  66. 66.
    Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;67:86.PubMedGoogle Scholar
  67. 67.
    Menter A, Reich K, Shu L, Guzzo C. Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical trials. J Am Acad Dermatol. 2008;58:Abstract 120.Google Scholar
  68. 68.
    Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol. 2008;58:609–16.PubMedGoogle Scholar
  69. 69.
    Papadavid E, Ferra D, Koumaki D, Dalamaga M, Stamou C, Theodoropoulos K, et al. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic. Dermatology. 2014;228:107–11.PubMedGoogle Scholar
  70. 70.
    Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667–74.PubMedGoogle Scholar
  71. 71.
    Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol. 2002;146:118.PubMedGoogle Scholar
  72. 72.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014.PubMedGoogle Scholar
  73. 73.
    Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842.PubMedGoogle Scholar
  74. 74.
    Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003;48:68.PubMedGoogle Scholar
  75. 75.
    Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49(Suppl. 2):S112–7.PubMedGoogle Scholar
  76. 76.
    Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598.PubMedGoogle Scholar
  77. 77.
    Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106.PubMedGoogle Scholar
  78. 78.
    Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844.PubMedGoogle Scholar
  79. 79.
    Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665.PubMedGoogle Scholar
  80. 80.
    Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675.PubMedGoogle Scholar
  81. 81.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371:326.PubMedGoogle Scholar
  82. 82.
    Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082.PubMedGoogle Scholar
  83. 83.
    Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31:1686.PubMedGoogle Scholar
  84. 84.
    Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79:824.PubMedGoogle Scholar
  85. 85.
    Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273.PubMedGoogle Scholar
  86. 86.
    Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78:81.PubMedGoogle Scholar
  87. 87.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405.PubMedGoogle Scholar
  88. 88.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418.PubMedGoogle Scholar
  89. 89.
    Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276.PubMedGoogle Scholar
  90. 90.
    Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79:302.PubMedGoogle Scholar
  91. 91.
    Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79:266.PubMedGoogle Scholar
  92. 92.
    Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014;71:484.PubMedGoogle Scholar
  93. 93.
    Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol. 2005;153:549.PubMedGoogle Scholar
  94. 94.
    Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, et al. Oral fumaric acid esters for psoriasis. Cochrane Database Syst Rev. 2015;(8):CD010497.Google Scholar
  95. 95.
    Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79:277.PubMedGoogle Scholar
  96. 96.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650.PubMedGoogle Scholar
  97. 97.
    Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668.PubMedGoogle Scholar
  98. 98.
    Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379:1313.PubMedGoogle Scholar
  99. 99.
    Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552.PubMedGoogle Scholar
  100. 100.
    Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949.PubMedGoogle Scholar
  101. 101.
    Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74:841.PubMedGoogle Scholar
  102. 102.
    Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, et al. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. Br J Dermatol. 2019;180:67.PubMedGoogle Scholar
  103. 103.
    Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trüeb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(12):1435–44.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Daniel Asz-Sigall
    • 1
  • Antonella Tosti
    • 2
  1. 1.National University of Mexico, Department of Onco-dermatology and Trichology ClinicMexico CityMexico
  2. 2.Fredric Brandt Endowed Professor of Dermatology, Dr. Phillip Frost Department of Dermatology and Cutaneous SurgeryUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations